Slingshot members are tracking this event:

Portola (PTLA) Expects BLA Re-Submission in Q2 for Andexxa (Anadexanet Alfa)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
Andexanet alfa is being developed as a universal reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled bleeding event or who require urgent or emergent surgery
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Biologics License Application, Bla, Andexxa, Serious Uncontrolled Bleeding Event, Urgent, Emergent Surgery, Andexanet Alfa